PD-1 products continue to be launched, and the "involution" of related pharmaceutical companies will continue to intensify

In March this year, the innovative PD-1 inhibitor slulimumab (HLX10, trade name: Hansi-like) independently developed by Shanghai Fuhong Henlius Biotechnology Co.
, Ltd.
was officially approved by the China National Medical Products Administration (NMPA).
Approved for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) adult patients with previously treated advanced solid tumors
.
It is worth noting that with the recent approval of Henlius’ PD-1 slulimumab, the number of PD-1 products on the domestic market has risen to nine.
Except for two imported products, the others are domestically produced
.
Specifically, they are Toripalizumab from Junshi Bio, Sintilimab from Innovent Bio, Carrelizumab from Hengrui Medicine, Tislelizumab from BeiGene, Acefang Bio's Piamprimab, and Yuheng Pharmaceutical's Sepalizumab
.
At present, with the continuous approval and marketing of PD-1/PD-L1 monoclonal antibody products, the sales of these products have also attracted the attention of the industry
.
Below, the author simply sorted out the sales of 6 PD-1 products that have been launched in 2021, and shared them with you
.
According to Junshi Bio’s annual report, toripalimab’s annual sales revenue in 2021 is only 412 million yuan, a drop of nearly 60% compared to the 2020 sales of 1.
003 billion yuan.
It is also the year with lower annual sales since the drug was approved at the end of 2018, and its first-year sales performance was 778 million
.
When evaluating the sales performance of PD-1 in the annual report, Junshi Bio said that although the sales volume in 2021 has increased, it has failed to achieve "price-for-volume", resulting in negative growth in sales revenue
.
However, on April 1, Junshi Biology stated on the investor interaction platform that the FDA's BLA review of toripalimab is proceeding as planned, the company has successfully completed the online part of the on-site inspection of the production base, and is waiting for the FDA Schedule the next phase of offline verification
.
In this regard, the industry expects that if it can be successfully approved for listing in the future, sales may usher in growth
.
On March 31, the 2021 annual results released by Kangfang Biologics showed that since its launch in August 2021, the sales of Piamprimab will be about 212 million yuan.

.
Combined with the CTLA-4 monoclonal antibody licensed to Merck & Co.
by AescoBio, which has entered the phase III clinical research stage, the company received a corresponding milestone payment of 129 million yuan, and the two together generated about 340 million yuan in revenue for Aescobio
.
It should be noted that in 2021, Kangfang Bio has successively applied for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer and the third-line treatment of metastatic nasopharyngeal carcinoma.
It is expected to be approved for listing
.
In this regard, the industry predicts that with the expansion of the approved indications of Piamprimab, its sales may usher in more volume
.
Sintilimab Innovent's PD-1 inhibitor "sintilimab" was rejected by the US FDA on March 24, although it was blocked from going overseas
.
However, as the leading product of Innovent Bio, sintilimab has accumulated revenue of more than 6.
4 billion yuan from its launch to the end of 2021, maintaining strong growth in both sales revenue and sales volume, and continues to be hot
.
As one of BeiGene's leading products, tislelizumab will contribute US$255.
1 million in sales revenue in 2021, or approximately RMB 1.
621 billion, compared with 1.
12 billion last year, a year-on-year increase of more than 40%
.
Regarding the reasons for the growth, BeiGene stated in the announcement that it was mainly due to the demand for new patients brought about by the expansion of medical insurance reimbursement, the further expansion of the sales team and the increase in the number of drugs entering the hospital
.
Since the 2021 annual report of Hengrui Medicine has not yet been released, its sales performance is not yet known, but Hengrui Medicine said in its previously released financial report for the first half of 2021 that camrelizumab is difficult to enter the hospital due to the product’s difficulty in entering the hospital.
There are many problems such as the different implementation time of medical insurance, and the sales revenue showed a negative growth month-on-month
.
At present, Yuheng Pharmaceutical has not disclosed its 2021 annual report, so the sales performance of sapalimumab is not known yet, but its price of 3,300 yuan per bottle of 120mg (4ml) has refreshed the domestic PD-1 price.
price
.
Conclusion In general, with the continuous approval of PD-1/PD-L1 monoclonal antibody products, the "involution" faced by market competition will intensify.

.
The industry expects that products with more indications may usher in a broader market in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.